Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals

por Ponchel, Frederique, Duquenne, Laurence, Xie, Xuanxiao, Corscadden, Diane, Shuweihdi, Farag, Mankia, K, Trouw, L A, Emery, Paul
Publicado 2022

Anti‐C1q autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a single‐centre, cross‐sectional study

por Dijkstra, D.J., Liem, S.I.E., van Leeuwen, N.M., Fehres, C.M., de Vries‐Bouwstra, J.K., Trouw, L.A.
Publicado 2021

Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands

por van Zanten, A, Arends, S, Roozendaal, C, Limburg, P C, Maas, F, Trouw, L A, Toes, R E M, Huizinga, T W J, Bootsma, H, Brouwer, E
Publicado 2017

Role of Anti–Carbamylated Protein Antibodies Compared to Anti–Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First‐Degree Relatives...

por Koppejan, H., Trouw, L. A., Sokolove, J., Lahey, L. J., Huizinga, T. J. W., Smolik, I. A., Robinson, D. B., El‐Gabalawy, H. S., Toes, R. E. M., Hitchon, C. A.
Publicado 2016

Complex medical history of a patient with a compound heterozygous mutation in C1QC

por Lubbers, R, Beaart-van de Voorde, L J J, van Leeuwen, K, de Boer, M, Gelderman, K A, van den Berg, M J, Ketel, A G, Simon, A, de Ree, J, Huizinga, T W J, Steup-Beekman, G M, Trouw, L A
Publicado 2019

Carbamylation reduces the capacity of IgG for hexamerization and complement activation

por Lubbers, R., Oostindie, S. C., Dijkstra, D. J., Parren, P. W. H. I., Verheul, M. K., Abendstein, L., Sharp, T. H., de Ru, A., Janssen, G. M. C., van Veelen, P. A., van den Bremer, E. T. J., Bleijlevens, B., de Kreuk, B.‐J., Beurskens, F. J., Trouw, L. A.
Publicado 2020